Dispersal history of SARS-CoV-2 in Galicia, Spain - Gallego-García, Pilar; Estévez-Gómez, Nuria; De Chiara, Loretta; Alvariño, Pilar; Juiz-González, Pedro M.; Torres-Beceiro, Isabel; Poza, Margarita; Vallejo, Juan A.; Rumbo-Feal, Soraya; Conde-Pérez, Kelly; Aja-Macaya, Pablo; Ladra, Susana; et al. (medRxiv, 2024)
The dynamics of SARS-CoV-2 transmission are influenced by a variety of factors, including social restrictions and the emergence of distinct variants. In this study, we delve into the origins and dissemination of the Alpha, Delta, and Omicron variants of concern in Galicia, northwest Spain. For this, we leveraged genomic data collected by the EPICOVIGAL Consortium and from the GISAID database, along with mobility information from other Spanish regions and foreign countries. Our analysis indicates that initial introductions during the Alpha phase were predominantly from other Spanish regions and France. However, as the pandemic progressed, introductions from Portugal and the USA became increasingly significant. Notably, Galicia’s major coastal cities emerged as critical hubs for viral transmission, highlighting their role in sustaining and spreading the virus. This research emphasizes the critical role of regional connectivity in the spread of SARS-CoV-2 and offers essential insights for enhancing public health strategies and surveillance measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was funded by grant EPICOVIGAL FONDO SUPERA-COVID19 from Banco Santander-CSIC-CRUE and grant CT850A-2 from ACIS SERGAS from the Consellería de Sanidade Xunta de Galicia. PGG was supported by grant ED481A-2021/345 from the Consellería de Cultura, Educación e Universidade Xunta de Galicia. SD acknowledges support from the Fonds National de la Recherche (F.R.S.-FNRS, Belgium; grant no. F.4515.22). SD and GB acknowledge support from the Research Foundation - Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, FWO, Belgium; grant no. G098321N) and from the European Union Horizon RIA 2023 project LEAPS (grant no. 101094685). GB acknowledges support from the Internal Funds KU Leuven (Grant No. C14/18/094), from the Research Foundation - Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, FWO, Belgium; grant no. G0E1420N) and from the DURABLE EU4Health project 02/2023-01/2027, which is co-funded by the European Union (call EU4H-2021-PJ4; grant no. 101102733). SD and PL acknowledge support from the European Union Horizon 2020 project MOOD (grant agreement no. 874850). PL and MAS acknowledge support from the European Union’s Horizon 2020 research and innovation programme (grant agreement no. 725422 - ReservoirDOCS), from the Wellcome Trust through project 206298/Z/17/Z and from the National Institutes of Health grants R01 AI153044, R01 AI162611 and U19 AI135995. PL also acknowledges support from the Research Foundation - Flanders (Fonds voor Wetenschappelijk Onderzoek - Vlaanderen, G0D5117N, and G051322N); MIV, JCS and NSO acknowledge support from the Foundation for Science and Technology (FCT) (project UIDB/50026/2020, UIDP/50026/2020).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Research Ethics Committee of Pontevedra-Vigo-Ourense (code 2020/422) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll genome sequences and associated metadata in this dataset are published in GISAID’s EpiCoV database. To view the contributors of each individual sequence with details such as accession number, Virus name, Collection date, Originating Lab, Submitting Lab, and the list of Authors, visit https://epicov.org/epi3/epi_set/240124ms (EPI_SET_ID: EPI_SET_240124ms, Supplementary Table 3).